Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.
Psyence BioMed today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development.
Psyence Biomed today announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel has granted Psyence Biomed an extension until December 31st, 2024, to demonstrate compliance with all Nasdaq continued listing rules.
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions - Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025
Pursuant to this licensing agreement, PsyLabs will supply Psyence Biomed with pharmaceutical-grade, EU GMP nature-derived (non-synthetic) psilocybin to be evaluated in future clinical trials as a potential treatment for AUD and other SUDs, and for commercialization of the licensed product. Psyence Biomed plans to lead with a clinical trial in AUD, Psyence Biomed’s second development indication.
